New data shows high rates of untreated Tardive Dyskinesia in long-term care patients

A recent study highlighted alarming findings regarding the treatment of Tardive Dyskinesia among long-term care patients. Conducted by Teva, the research revealed that a staggering 75% of these patients receive incorrect treatment or none at all for this debilitating disorder. Tardive Dyskinesia, often resulting from prolonged use of antipsychotic medications, requires timely and accurate medical intervention. The study emphasizes a critical gap in care strategies within long-term care facilities, urging healthcare providers to address this oversight. As the population in care facilities continues to grow, the need for effective treatment protocols becomes increasingly essential. The findings call for enhanced awareness and education about Tardive Dyskinesia to improve patient outcomes. Improving overall healthcare management can significantly reduce the incidence of undertreatment and ensure better quality of life for affected patients.

Stock Titan